As Loxo Oncology INC (LOXO) Share Value Rose, Dafna Capital Management LLC Has Lowered Position by $3.82 Million

March 14, 2018 - By Adrian Erickson

Investors sentiment decreased to 1.73 in 2017 Q3. Its down 2.10, from 3.83 in 2017Q2. It turned negative, as 13 investors sold LOXO shares while 35 reduced holdings. 31 funds opened positions while 52 raised stakes. 29.06 million shares or 49.34% less from 57.37 million shares in 2017Q2 were reported. Columbia Wanger Asset Management Limited Company invested in 534,279 shares or 0.73% of the stock. Sei Invs has invested 0% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Perigon Wealth Mngmt Lc holds 100 shares. First Personal Fincl has invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Tiaa Cref Inv Ltd Limited Liability Company stated it has 0% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). 2,300 are held by Cambridge Investment Research. Bancshares Of America Corporation De has 13,769 shares. Boothbay Fund Mngmt Limited Liability Corporation accumulated 2,326 shares. Aqr Mngmt Ltd Co owns 27,082 shares or 0% of their US portfolio. Great West Life Assurance Com Can reported 2,958 shares. Barclays Public Limited Liability Corp, a United Kingdom-based fund reported 2,665 shares. Vident Inv Advisory Limited Company invested 0.02% in Loxo Oncology, Inc. (NASDAQ:LOXO). Zurcher Kantonalbank (Zurich Cantonalbank) reported 825 shares or 0% of all its holdings. Neuberger Berman Group Inc Lc has 0% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 4,500 shares. Metropolitan Life Ins reported 0.01% stake.

Since September 18, 2017, it had 0 insider buys, and 18 insider sales for $70.77 million activity. Shares for $271,866 were sold by Van Naarden Jacob. Another trade for 15,000 shares valued at $1.45 million was made by Bilenker Joshua H. on Monday, February 12. 1,700 shares valued at $151,470 were sold by Burstein Jennifer on Monday, September 18. Bonita David P also sold $20.63 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares. 250,000 shares were sold by AISLING CAPITAL III LP, worth $20.13 million. 250,000 shares were sold by ORBIMED ADVISORS LLC, worth $20.63M.

Nathan Fischel decreased its stake in Loxo Oncology Inc (LOXO) by 13.67% based on its latest 2017Q3 regulatory filing with the SEC. Dafna Capital Management Llc sold 41,500 shares as the company’s stock rose 10.54% with the market. The hedge fund run by Nathan Fischel held 262,121 shares of the health care company at the end of 2017Q3, valued at $24.15 million, down from 303,621 at the end of the previous reported quarter. Dafna Capital Management Llc who had been investing in Loxo Oncology Inc for a number of months, seems to be less bullish one the $3.97 billion market cap company. The stock decreased 0.48% or $0.64 during the last trading session, reaching $132.23. About 191,482 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 77.12% since March 14, 2017 and is uptrending. It has outperformed by 60.42% the S&P500.

Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on May, 8. They expect $-0.44 EPS, up 54.17 % or $0.52 from last year’s $-0.96 per share. After $-0.69 actual EPS reported by Loxo Oncology, Inc. for the previous quarter, Wall Street now forecasts -36.23 % EPS growth.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: which released: “Should You Buy Loxo Oncology (LOXO) Ahead of Earnings?” on February 28, 2018, also with their article: “Orbimed Advisors Llc Buys Regeneron Pharmaceuticals Inc, Amicus Therapeutics …” published on March 13, 2018, published: “Loxo Oncology Reaches Analyst Target Price” on February 22, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: and their article: “Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results” published on March 01, 2018 as well as‘s news article titled: “Loxo Oncology to Present at the Cowen and Company 38th Annual Health Care …” with publication date: March 06, 2018.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 11 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 10 have Buy rating, 1 Sell and 0 Hold. Therefore 91% are positive. Loxo Oncology Inc had 33 analyst reports since July 29, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Loxo Oncology, Inc. (NASDAQ:LOXO) on Wednesday, November 11 with “Buy” rating. The company was maintained on Monday, June 5 by BTIG Research. The stock has “Outperform” rating by Cowen & Co on Thursday, August 27. The stock has “Buy” rating by Morgan Stanley on Monday, June 19. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Buy” rating by Citigroup on Monday, March 5. Oppenheimer maintained the shares of LOXO in report on Tuesday, August 4 with “Buy” rating. The rating was upgraded by Zacks to “Sell” on Friday, August 28. The rating was maintained by Citigroup on Wednesday, March 16 with “Buy”. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, September 27. The rating was maintained by Stifel Nicolaus on Tuesday, August 8 with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.